Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04350892 · ClinicalTrials.gov registry record · NA
Cerebrospinal Fluid Biomarkers in Bariatric Surgery
A NA study, sponsored by Columbia University.
- Completed
- Registry status
- NA
- Development phase
- 51
- Enrollment target
NCT04350892 is a NA study that has completed, run by Columbia University. The registered enrollment target is 51 participants.
The verdict
NCT04350892, a NA study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- NA
- Development phase
- 51 participants
- Enrollment target
Study Summary
The goal of this project is to understand why bariatric surgery is such an effective treatment for obesity with a focus on brain mechanisms. Cerebrospinal fluid (CSF) neuropeptide, hormone and protein levels will be measured as a surrogate for changes in brain activity in participants before and after bariatric surgery as compared with participants before and after diet-induced weight loss. The investigators are studying neuropeptides and hormones that are know to be involved with the regulation of appetite and body weight to determine if some of the changes that are expected to occur after diet-induced weight loss do not occur after bariatric surgery. In addition, proteomic analysis will be used to uncover new protein biomarkers that are unique to surgical weight loss. The results of these studies will help explain why bariatric surgery is so effective in achieving long-term weight loss. Understanding how the central nervous system responds to bariatric surgery could help the development of alternative nonsurgical therapies for obesity and its metabolic complications.
Interventions
- PROCEDURE Roux-en-Y Gastric Bypass (RYGB)
- PROCEDURE Sleeve Gastrectomy (SG)
- BEHAVIORAL Very Low Calorie Diet (VLCD)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2020-10-20 |
| Est. Completion | 2025-12-29 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04350892
The ClinicalTrials.gov registry entry for NCT04350892 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Roux-en-Y Gastric Bypass (RYGB) is the first listed.
NCT04350892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04350892 about?
NCT04350892 is a clinical study titled "Cerebrospinal Fluid Biomarkers in Bariatric Surgery". The goal of this project is to understand why bariatric surgery is such an effective treatment for obesity with a focus on brain mechanisms. Cerebrospinal fluid (CSF) neuropeptide, hormone and protein levels will be measured as a surrogate for changes in brain activity in participants before and aft...
What is the current status of trial NCT04350892?
This trial is currently completed. It is a NA study. The enrollment target is 51 participants. The study started on 2020-10-20. Estimated completion is 2025-12-29.
What interventions are being tested in trial NCT04350892?
The interventions under investigation include: Roux-en-Y Gastric Bypass (RYGB) (PROCEDURE), Sleeve Gastrectomy (SG) (PROCEDURE), Very Low Calorie Diet (VLCD) (BEHAVIORAL).
Who is sponsoring clinical trial NCT04350892?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.